INTRODUCTION
Cyclosporin A (CyA; Figure 1 ), a cyclic undecapeptide with a 33-membered ring, exerts several biological properties, including anti-fungal, anti-parasitic, anti-inflammatory and immunosuppressive activities (Borel, 1986) . Because of its immunosuppressive potential, it is widely used in human transplantation surgery (Kahan, 1984) and in the treatment of autoimmune diseases (Schindler, 1985) . CyA is produced by the fungus Beauveria nivea (previously designated as Tolypocladium inflatum; see Lawen and Zocher, 1990) as the main product of at least 25 so-called 'natural' cyclosporins (Traber et al., 1987) . With the exception of cyclosporin H (CyH; CyA, i.e. CyA with Dmethylvaline at position 11) all ofthese cyclosporins are produced by cyclosporin synthetase (Lawen and Zocher, 1990) , which possesses rather broad substrate specificity at most of its active sites (Lawen et al., 1989; Lawen and Traber, 1993) . This enzyme is a very complex multifunctional polypeptide, consisting of a single polypeptide chain with a molecular mass of at least 1.4 mDa (Schmidt et al., 1992) . It catalyses all 40 reaction steps necessary for the biosynthesis of cyclosporin A starting from the unmethylated constituent amino acids (Lawen and Zocher, 1990) .
In 1988, a novel cyclosporin-related peptolide, with several substitutions compared with CyA, called SDZ 214-103 was discovered. It is produced by the fungus Cylindrotrichum oligospermum (Corsa) BONORDEN (Dreyfuss et al., 1989 (Lawen et al., 1991b) . The molecular mass of this enzyme is similar to that of cyclosporin synthetase (Lawen et al., 1991a) but its substrate specificity appears, as far as it has been analysed, to be much show immunosuppressive activity. The cyclosporin synthetaserelated enzyme peptolide SDZ 214-103 synthetase, on the other hand, does not incorporate either ,J-alanine into position 7 or fihydroxy acids into position 8, confirming the previously described higher substrate specificity of this enzyme compared with cyclosporin synthetase [Lawen and Traber (1993) J. Biol. Chem. 268, 20452-20465] .
narrower than that ofcyclosporin synthetase (Lawen and Traber, 1993) .
We 
MATERIALS AND METHODS
Organisms and culture conditions B. nivea, strain 7939/45, was maintained and grown in submerged culture as previously described for enzyme production (Lawen et al., 1989) and for the fermentation of [D-Ser8]CyA . Maintenance and culture of C. oligospermum (Corda) BONORDEN, strain 85-22651/F, isolate 5.1.15 was carried out as reported earlier (Lawen et al., 1991b; Lawen and Traber, 1993 
semisynthesis as described previously (Eberle, 1991 Enzyme preparations and in vitro peptide formation Preparations of cyclosporin synthetase and peptolide SDZ 214-103 synthetase from mycelia of B. nivea or C. oligospermum respectively were performed according to previously described procedures (Lawen and Zocher, 1990; Lawen et al., 1991b; Lawen and Traber, 1993) . In vitro cyclosporin and peptolide formation and extraction of the products were also carried out as reported previously (Lawen et al., 1989; Lawen and Traber, 1993 (Lawen et al., 1989 'H-n.m.r. spectroscopy 'H-n.m.r. spectra were recorded in C2HC13 at 24°C with a Bruker AMX-400 spectrometer. All 'H-resonance lines of CyA had been assigned previously (Kessler et al., 1985) . Correlation spectroscopy (COSY) and rotating-frame Overhauser enhancement spectroscopy (ROESY) data were recorded with a spectral width of 3601 Hz in w2 and oil; 32 scans of 256 increments in t1 were acquired. The mixing time for the ROESY spectrum was 150 ms. The data were processed using standard Bruker software.
Biological assays
The in vitro immunosuppressive activity of the cyclosporins was determined as described (Schreier et al., 1992) . Growth imp., 2,6-di-t-butyl-4-methylphenol (impurity). (Figure 2 ) with the spectral data of CyA (Kessler et al., 1985) , the differences in the chemical structures became evident ( CyA during the extraction process, it seemed unlikely that the enzyme would have the flexibility to form either a 33-or a 34-membered ring. We therefore examined whether [fiAla8]CyA could be a product of direct enzymic synthesis by using our previously described in vitro cyclosporin biosynthesis system (Lawen et al., 1989; Lawen and Traber, 1993 (400 MHz, C2HCI) compound with an a-value of 6.79 and which co-eluted with authentic [/?Ala8]CyA was isolated. As outlined in Table 2 , the f.a.b.-m.s. spectrum showed a molecular ion peak at 1202 (M+ H+) and the in vitro immunosuppressive activity was measured to be -10-fold less than that of CyA. All the data support the interpretation that this compound is [JAla8]CyA. Three minor compounds were also separated in this experiment, but only one of them could be identified. 10 lug of [Gly7 8]CyA with an a-value of 5.36 and a molecular ion peak at 1174 (M+ H+) was isolated. It had been shown previously that cyclosporin synthetase produces as the major product [Gly8]CyA, when D-Ala is omitted from the incubation mixture, and also produces [Gly7]CyA when Ala is omitted from incubation mixture (Lawen and Traber, 1993 Search for blosynthesis of further ring-expanded cyclosporin homologues A new product could also be detected with Ala was replaced with /JAla in the incubation mixture ( Figure 4A, lane 3) . Because no reference [/JAla7]CyA was available, we had to perform three preparative incubations to identify this cyclosporin. We could isolate up to five different cyclosporins, four of which could be identified. Experiment 1 yielded 10 jug of cyclosporin (I), 5 ,ug of cyclosporin (II), 25 ,g of cyclosporin (III), 70 etg of cyclosporin (IV) and 70 ,ug of cyclosporin (V); experiment 2 yielded 10 jtg of cyclosporin (I), 10 ,ug of cyclosporin (II), 20 ,ug of cyclosporin (III), 50 ,ug of cyclosporin (IV) and 80 ,ug of cyclosporin (V), and experiment 3 yielded 20 /ug of cyclosporin (III), 70 ,ug of cyclo- Table 2 Seiected properties of products from incubaftons designed to form fiAla-containing cyclosporins For each incorporation experiment, three assays were performed: one with all constitutive amino acids of CyA, a second without D-Ala or Ala and a third with /lAla instead of the az-alanine. The extracts of the incubation mixtures were analysed as described in the Materials and methods section. The a-factor is defined as the relative retention time 1O[(tRI -to)/(tR2 -to)] where tRl and tR2 are the corresponding retention times and 4 is the retention time of the dead volume. CyA was used as the reference compound (a = 10.00). Immunosuppressive activity is described as: + + +, strong immunosuppressive activity; + +, moderate activity. n.d., not determined. Table 2 , and from our assay conditions, we concluded that this compound is the expected [/JAla7]CyA.
D-Ala at position 8 of CyA has been shown to be the starting amino acid in the biosynthetic process Dittmann et al., 1994) . Thus, ring extension occurs at the cyclization site. To clarify whether the capability to extend the peptide ring by one carbon at positions 7 or 8 is a general phenomenon for this family of multienzyme polypeptides, we also examined the cyclosporin synthetase-related peptolide SDZ 214-103 synthetase (Lawen et al., 1991b) . The product of this enzyme, peptolide SDZ 214-103, has a D-2-hydroxyisovaleric acid at position 8 (instead of the D-Ala in cyclosporin A). At position 7, SDZ 214-103 carries, like CyA, an Ala moiety. We tested the capability of SDZ 214-103 synthetase to introduce into position 8 a series of 3-hydroxy acids (or the appropriate lactones), namely mevalonic acid lactone, D-(-)f-hydroxybutyric acid and ,6-propiolactone. According to its previously published substrate specificity (Lawen and Traber, 1993) , at least the latter two compounds should be substrates of the enzyme, if only the side chain is restricting and the enzyme allows ring extension. However, the synthetase did not incorporate any of these compounds or fl-Ala (Figure 4b ). Therefore, it remains an open question, whether the ability to produce peptides with a ring extension at the cyclization site is a specific feature of cyclosporin synthetase, or whether the failure to do that is an unusual property of peptolide SDZ 214-103 synthetase. It would therefore be of interest to examine further multienzyme polypeptides, e.g. SDZ 90-215 synthetase (Lee and Lawen, 1993) , for their capability to synthesize ring-extended products.
